Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2026—Evidence-based guidelines for platelet use help prevent unnecessary transfusion and inform better transfusion practice. Platelet transfusions can be used to prophylactically prevent bleeding or treat bleeding.
October 2026—Primary endometrial carcinomas with somatically-derived yolk sac tumor components are rare. Therefore, the authors performed detailed clinicopathologic, immunohistochemical, and molecular analyses to better understand and address these entities.
October 2026—Artificial intelligence studies in the realm of pathology increasingly demonstrate the impressive diagnostic performance of AI, but it is also worthwhile to understand what happens when these tools are incorporated into routine clinical practice. To this end, the authors evaluated the validation, implementation, and real-world impact of an AI–assisted decision-support tool for prostate needle biopsies within a fully digital pathology practice.
October 2026—Bladder cancer is diagnosed and monitored using cystoscopy, an invasive procedure in which a camera is inserted into the bladder. Because this type of cancer recurs in more than 50 percent of patients within five years, such patients require repeated cystoscopies for the rest of their lives, creating significant discomfort, cost, and clinical burden.
October 2026
Q. For laboratories that have a remote laboratory information system (LIS), what documentation is needed to show compliance with CAP checklist requirement GEN.42195 Remote LIS? Read answer.
Q. Practice and confidence make the biggest difference in microtomy speed. Are there minor details beginner histotechnologists might overlook that could hinder their progress? Read answer.
October 2026—Marie, Elara, and Stanley are the children of Abdul Hamid Halabi and his pathologist wife, Gazal Alsaati, MD, but not in the traditional sense. Instead, they are a suite of artificial intelligence-based apps born of the couple’s company, Clinlab.AI.
Mayo Clinic on Sept. 15 announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific, to help transform how the life sciences community understands the biological changes that occur as people move from health toward disease.
September 2026—Though it may test the memory of many, there once was a time when HER2 immunohistochemistry was a relatively uncomplicated matter. Back in September 1998, the FDA approved both trastuzumab (Herceptin) and the first companion diagnostic assay, HercepTest, which was used to determine whether patients with metastatic breast cancer could receive the new drug.
September 2026—When Heidi Rehm, PhD, and other researchers examined more than 1.5 million diagnostic sequencing test results from 19 clinical laboratories, they found an astonishing rate of inconclusive reports due to variants of uncertain significance—nearly a third in diagnostic multigene panel testing.
September 2026—Amyloidosis has become a treatable disease—if the fibril type is identified accurately and quickly. That and the variability seen in its workup and diagnosis were the impetus for the recently published CAP amyloidosis guideline. The co-chairs of the guideline expert panel provided, in a CAP25 session, what they described as their own tips and tricks for amyloid detection and fibril typing, reported here.
